SG11202105338VA - Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections - Google Patents
Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infectionsInfo
- Publication number
- SG11202105338VA SG11202105338VA SG11202105338VA SG11202105338VA SG11202105338VA SG 11202105338V A SG11202105338V A SG 11202105338VA SG 11202105338V A SG11202105338V A SG 11202105338VA SG 11202105338V A SG11202105338V A SG 11202105338VA SG 11202105338V A SG11202105338V A SG 11202105338VA
- Authority
- SG
- Singapore
- Prior art keywords
- heteroaryldihydropyrimidine
- infections
- derivatives
- methods
- treating hepatitis
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2018122258 | 2018-12-20 | ||
| US201962791576P | 2019-01-11 | 2019-01-11 | |
| PCT/CN2019/126739 WO2020125730A1 (fr) | 2018-12-20 | 2019-12-19 | Dérivés d'hétéroaryldihydropyrimidine et procédés de traitement d'infections par le virus de l'hépatite b |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202105338VA true SG11202105338VA (en) | 2021-07-29 |
Family
ID=71102522
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202105338VA SG11202105338VA (en) | 2018-12-20 | 2019-12-19 | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis b infections |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230165865A1 (fr) |
| EP (1) | EP3898632A4 (fr) |
| JP (1) | JP2022513297A (fr) |
| KR (1) | KR20210106464A (fr) |
| CN (1) | CN113195499A (fr) |
| AU (1) | AU2019410640A1 (fr) |
| BR (1) | BR112021011858A2 (fr) |
| CA (1) | CA3118764A1 (fr) |
| IL (1) | IL284116A (fr) |
| MA (1) | MA54556A (fr) |
| MX (1) | MX2021007602A (fr) |
| SG (1) | SG11202105338VA (fr) |
| TW (1) | TW202035412A (fr) |
| WO (1) | WO2020125730A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018291688B2 (en) | 2017-06-27 | 2022-02-03 | Janssen Pharmaceutica Nv | Heteroaryldihydropyrimidine derivatives and methods of treating hepatitis B infections |
| US11053235B2 (en) | 2018-08-09 | 2021-07-06 | Janssen Sciences Ireland Unlimited Company | Substituted 1,4-dihydropyrimidines for the treatment of HBV infection or HBV-induced diseases |
| JP2022511819A (ja) * | 2018-12-20 | 2022-02-01 | ヤンセン ファーマシューティカ エヌ．ベー． | ヘテロアリールジヒドロピリミジン誘導体及びｂ型肝炎感染症を治療する方法 |
| CN111825676B (zh) * | 2019-04-15 | 2023-10-17 | 广东东阳光药业股份有限公司 | 二氢嘧啶类化合物及其在药物中的应用 |
| WO2020255016A1 (fr) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de dihydropyrimidine en tant que modulateurs de l'assemblage des capsides |
| WO2020255017A1 (fr) * | 2019-06-18 | 2020-12-24 | Janssen Sciences Ireland Unlimited Company | Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de dihydropyrimidine en tant que modulateurs d'assemblage de capside |
| AR124719A1 (es) | 2021-01-29 | 2023-04-26 | Janssen Sciences Ireland Unlimited Co | Derivados de dihidropirimidina y usos de estos en el tratamiento de la infección por vhb o de enfermedades inducidas por vhb |
| EP4293022A1 (fr) * | 2021-02-09 | 2023-12-20 | Shanghai Visonpharma Co., Ltd. | Composé de dihydropyrimidine, son procédé de préparation et son utilisation |
| WO2022257942A1 (fr) | 2021-06-09 | 2022-12-15 | Janssen Sciences Ireland Unlimited Company | Dérivés de dihydropyrimidine et leurs utilisations dans le traitement d'une infection au vhb ou de maladies induites par le vhb |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014037480A1 (fr) * | 2012-09-10 | 2014-03-13 | F. Hoffmann-La Roche Ag | Hétéroaryldihydropyrimidines d'acide 6-aminé pour le traitement et la prophylaxie d'une infection par le virus de l'hépatite b |
| JP6533217B2 (ja) * | 2013-05-17 | 2019-06-19 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｂ型肝炎ウイルス感染症の治療および予防のための６−架橋ヘテロアリールジヒドロピリミジン類 |
| CA2935811C (fr) * | 2014-03-07 | 2018-09-18 | F. Hoffmann-La Roche Ag | Nouvelles heteroaryldihydropyrimidines condensees en position 6 pour le traitement et la prophylaxie d'une infection a virus de l'hepatite b |
| MY196243A (en) * | 2014-03-28 | 2023-03-24 | Sunshine Lake Pharma Co Ltd | Dihydropyrimidine Compounds and Their Application In Pharmaceuticals |
| PT3270915T (pt) * | 2015-03-16 | 2020-06-17 | H Hoffnabb La Roche Ag | Tratamento combinado com um agonista do tlr7 e um inibidor da montagem da cápside do vhb |
| WO2017064156A1 (fr) * | 2015-10-16 | 2017-04-20 | F. Hoffmann-La Roche Ag | Nouvelles 2-hétéroaryldihydropyrimidines fusionnées en position 6 pour le traitement et la prophylaxie de l'infection par le virus de l'hépatite b |
| AR107633A1 (es) * | 2016-02-19 | 2018-05-16 | Hoffmann La Roche | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico |
-
2019
- 2019-12-18 TW TW108146369A patent/TW202035412A/zh unknown
- 2019-12-19 US US17/415,712 patent/US20230165865A1/en active Pending
- 2019-12-19 MX MX2021007602A patent/MX2021007602A/es unknown
- 2019-12-19 SG SG11202105338VA patent/SG11202105338VA/en unknown
- 2019-12-19 MA MA054556A patent/MA54556A/fr unknown
- 2019-12-19 EP EP19897899.1A patent/EP3898632A4/fr not_active Withdrawn
- 2019-12-19 JP JP2021534914A patent/JP2022513297A/ja not_active Withdrawn
- 2019-12-19 BR BR112021011858A patent/BR112021011858A2/pt unknown
- 2019-12-19 CA CA3118764A patent/CA3118764A1/fr active Pending
- 2019-12-19 CN CN201980084849.2A patent/CN113195499A/zh active Pending
- 2019-12-19 WO PCT/CN2019/126739 patent/WO2020125730A1/fr unknown
- 2019-12-19 KR KR1020217020628A patent/KR20210106464A/ko not_active Application Discontinuation
- 2019-12-19 AU AU2019410640A patent/AU2019410640A1/en not_active Abandoned
-
2021
- 2021-06-17 IL IL284116A patent/IL284116A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL284116A (en) | 2021-08-31 |
| WO2020125730A1 (fr) | 2020-06-25 |
| TW202035412A (zh) | 2020-10-01 |
| US20230165865A1 (en) | 2023-06-01 |
| BR112021011858A2 (pt) | 2021-11-30 |
| MA54556A (fr) | 2021-10-27 |
| CA3118764A1 (fr) | 2020-06-25 |
| JP2022513297A (ja) | 2022-02-07 |
| CN113195499A (zh) | 2021-07-30 |
| MX2021007602A (es) | 2021-08-11 |
| KR20210106464A (ko) | 2021-08-30 |
| AU2019410640A1 (en) | 2021-05-27 |
| EP3898632A1 (fr) | 2021-10-27 |
| EP3898632A4 (fr) | 2023-02-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3898628A4 (fr) | Dérivés d'hétéroaryldihydropyrimidine et procédés de traitement d'infections par le virus de l'hépatite b | |
| IL284116A (en) | Heteroaryldihydropyrimidine history and methods of treating hepatitis B infections | |
| HK1247147A1 (zh) | 氮雜環辛烷和氮雜環壬烷衍生物以及治療乙型肝炎感染的方法 | |
| EP3472362C0 (fr) | Inhibiteurs papd7 et papd5 pour traiter une infection par l'hépatite b | |
| EP3240787A4 (fr) | Dérivés et méthodes de traitement d'infections provoquées par le virus de l'hépatite b | |
| IL246678A0 (en) | History of Azpan and methods of treating jaundice b infections | |
| IL257384A (en) | Preparations containing rnai and their use for the treatment of infection with the hepatitis b virus | |
| HK1251220A1 (zh) | 用於治療和預防乙型肝炎病毒感染的新的四環4-氧代-吡啶-3-甲酸衍生物 | |
| IL281277A (en) | Preparations and methods for treating viral infections | |
| EP3645516A4 (fr) | Dérivés hétéroaryldihydropyrimidine et méthodes de traitement d'infections par le virus de l'hépatite b | |
| HK1231402A1 (zh) | 治療 型肝炎和 型肝炎病毒感染的方法 | |
| IL263368A (en) | Prevention and treatment of viral infections | |
| SG11202103567RA (en) | Methods of treatment of inflammatory conditions and associated infections | |
| EP3509596C0 (fr) | Norketotifen pour le traitement de l'hypercytokinémie et l'infection virale | |
| EP3634431A4 (fr) | Compositions et méthodes thérapeutiques pour le traitement de l'hépatite b | |
| IL290792A (en) | Preparations and methods for treating viral infections | |
| HK1255835A1 (zh) | 用於治療乙型肝炎的治療組合物及方法 | |
| IL271987A (en) | Regimens for the treatment of HIV infections and AIDS | |
| PL3463469T3 (pl) | Kombinacja ledipaswiru i sofosbuwiru do zastosowania w leczeniu zakażeń wirusem zapalenia wątroby typu b u ludzi | |
| EP3675813A4 (fr) | Méthode et composition destinées à prévenir et à traiter des infections virales | |
| ZA202006569B (en) | Methods of treating fungal infections | |
| HK1254547A1 (zh) | 抗病毒劑和治療病毒感染的方法 | |
| EP3512550A4 (fr) | Compositions et procédés pour le traitement d'infections | |
| EP3606516A4 (fr) | Méthode de traitement et de prévention d'infections | |
| EP4077305A4 (fr) | Dérivés d'hétéroaryldihydropyrimidine et procédés de traitement d'infections par le virus de l'hépatite b |